Subscribe to stay informed!
Malvern-based Annovis Bio recently reported positive clinical trial results for buntanetap, the biopharmaceutical company’s lead new drug candidate in Parkinson’s disease patients…
Malvern-based Annovis Bio plans to focus on patients who have the early form of Alzheimer’s disease in the future development of its experimental…
Berwyn-based Annovis Bio is delaying the release of the late-stage study results of its experimental Parkinson’s disease treatment, writes John George for…
Positive news about Berwyn-based Annovis Bio’s experimental Alzheimer’s disease therapy bumped the company’s stock up by 16 percent Monday during mid…
A Berwyn-based biopharmaceutical company is filing for a patent for its new drug candidate that could potentially treat neurodegenerative diseases. Annovis Bio filed for…
Annovis Bio, a Berwyn-based biotech company, has managed to raise $8.7 million to advance its experimental treatment for Parkinson’s and Alzheimer’s…
Despite the disruptions caused by the coronavirus pandemic and labor shortages, Philadelphia experienced a venture capital boom in 2021, write Taylor Allen and Mike D…
Berwyn-based Annovis Bio is the latest in the line of Philadelphia-area biotech developers to sell shares to the public before having any sales…
Annovis Bio, the pharmaceutical company in Berwyn working on potential treatments for neurological disorders such as Alzheimer’s and Parkinson’s diseases, has filed for…
Before we send you to this site, please subscribe to our daily newsletter.
